Maprotiline

Maprotiline is a highly selective noradrenergic reuptake inhibitor that has strong antidepressant, antitumor and neuropathic pain-relieving effects. Maprotiline induces cancer cell apoptosis by targeting the ERK signaling pathway and CRABP1[1][2].

Product Specifications

CAS Number

[10262-69-8]

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Apoptosis; Autophagy; ERK

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/maprotiline.html

Solubility

10 mM in DMSO

Smiles

CNCCCC12C3=C(C=CC=C3)C(CC2)C4=CC=CC=C14

Molecular Formula

C20H23N

Molecular Weight

277.40

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Gunduz O, et al. Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice. Eur J Pain. 2016 Mar. 20 (3) :465-71.|[2]Zheng C, et al. Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1. Front Pharmacol. 2021 May 20. 12:689767.